Compare · MDLN vs XENT
MDLN vs XENT
Side-by-side comparison of Medline Inc. (MDLN) and Intersect ENT Inc. (XENT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and XENT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.08B, about 52.8x XENT ($911.2M).
- MDLN has hit the wire 7 times in the past 4 weeks while XENT has been quiet.
- MDLN has more recent analyst coverage (25 ratings vs 5 for XENT).
- Company
- Medline Inc.
- Intersect ENT Inc.
- Price
- $35.95-1.74%
- $28.25+0.02%
- Market cap
- $48.08B
- $911.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2014
- News (4w)
- 7
- 0
- Recent ratings
- 25
- 5
Intersect ENT Inc.
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL and PROPEL Mini, which are steroid releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M
Latest XENT
- FDA Approval for SINUVA issued to INTERSECT ENT INC
- SEC Form POSASR filed by Intersect ENT Inc.
- SEC Form RW WD filed by Intersect ENT Inc.
- Nalu Medical, Inc. Names Thomas West President and Chief Executive Officer
- SEC Form 15-12B filed by Intersect ENT Inc.
- SEC Form S-8 POS filed by Intersect ENT Inc.
- SEC Form EFFECT filed by Intersect ENT Inc.
- SEC Form 4 filed by Hattangadi Neil A
- SEC Form 4: Meier Richard A closing all direct ownership in the company
- SEC Form 4: Fernandez Reyna M closing all direct ownership in the company